Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
Open Access
- 13 August 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (19)
Abstract
BACKGROUND: Androgen receptor signaling inhibitors (ARSIs) have improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), but their clinical benefit is limited by treatment resistance. METHODS: To investigate the mechanisms of ARSI resistance, we analyzed the whole-genome ( n = 45) and transcriptome ( n = 31) sequencing data generated from paired metastatic biopsies obtained before initiation of first-line ARSI therapy for mCRPC and after radiographic disease progression. We investigated the effects of genetic and pharmacologic modulation of SSTR1 in 22Rv1 cells, a representative mCRPC cell line. RESULTS: We confirmed the predominant role of tumor genetic alterations converging on augmenting androgen receptor (AR) signaling and the increased transcriptional heterogeneity and lineage plasticity during the emergence of ARSI resistance. We further identified amplifications involving a putative enhancer downstream of the AR and transcriptional downregulation of SSTR1 , encoding somatostatin receptor 1, in ARSI-resistant tumors. We found that patients with SSTR1 -low mCRPC tumors derived less benefit from subsequent ARSI therapy in a retrospective cohort. We showed that SSTR1 was antiproliferative in 22Rv1 cells and that the FDA-approved drug pasireotide suppressed 22Rv1 cell proliferation. CONCLUSION: Our findings expand the knowledge of ARSI resistance and point out actionable next steps, exemplified by potentially targeting SSTR1, to improve patient outcomes. FUNDING: National Cancer Institute (NCI), NIH; Prostate Cancer Foundation; Conquer Cancer, American Society of Clinical Oncology Foundation; UCSF Benioff Initiative for Prostate Cancer Research; Netherlands Cancer Institute.Keywords
Funding Information
- Prostate Cancer Foundation (SU2C-AACR-DT0812)
- Instituto Nacional de Cancerología (1R01CA227025)
This publication has 106 references indexed in Scilit:
- Motif Enrichment Analysis: a unified framework and an evaluation on ChIP dataBMC Bioinformatics, 2010
- The Sequence Alignment/Map format and SAMtoolsBioinformatics, 2009
- MEME SUITE: tools for motif discovery and searchingNucleic Acids Research, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- Sfrp5 coordinates foregut specification and morphogenesis by antagonizing both canonical and noncanonical Wnt11 signalingGenes & Development, 2008
- Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation-refractory prostate cancer.2006
- Evidence that TRPM8 Is an Androgen-Dependent Ca2+ Channel Required for the Survival of Prostate Cancer CellsCancer Research, 2004
- Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic systemAnnals of Oncology, 2004
- Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptorNature Medicine, 2000
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995